for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ビジネス

Pfizer's premium bet on generic drugmaker

Drugmaker Pfizer is paying a 39 percent premium to buy Hospira in a bid to boost its portfolio of generic injectible drugs and copies of biotech drugs. Bobbi Rebell reports.

最新のビデオ
エンタテインメント
ライフ
スポーツ
テクノロジー

ビジネス

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up